Clinical Trial Update: Semaglutide 2.4 mg in Patients With Poor Weight-loss [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update indicates the semaglutide 2.4 mg study for patients with poor weight loss is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome
• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• WEGOVY (Semaglutide)

Snippet

Sponsor: University College, London | Conditions: Obesity, Diabetes | Phase 3 | Status: ACTIVE_NOT_RECRUITING